10/26/2026
FDA psychedelics docket draws mixed stakeholder responses
Stakeholders express varied opinions on FDA's recent psychedelics docket, highlighting diverse perspectives.
Topic archive
u.s. food and drug administration
21 stories
10/22/2026
Ibogaine Club Research Group advises FDA on trial safety
The group emphasizes cardiac risk management in ibogaine clinical trials.
10/22/2026
VA faces challenges in psychedelic treatment rollout
Federal officials discuss the complexities of psychedelic access for veterans.
10/14/2026
TELA Bio gains FDA clearance for resorbable surgical mesh
FDA approves TELA Bio's first in-house developed resorbable mesh, expanding their product line.
10/11/2026
FDA seeks public input on ibogaine trial safety
Ibogaine trials for opioid use disorder face scrutiny over safety.
10/9/2026
FDA seeks public input on ibogaine trials
Gabon aims to secure benefits from rising ibogaine demand
10/9/2026
FDA considers ibogaine clinical trials
Potential trials could explore ibogaine's role in treating opioid addiction.
10/8/2026
FDA proposes ibogaine trial design, seeks input
FDA outlines early-stage ibogaine trial design, inviting public feedback.
10/6/2026
US funds ibogaine trials for opioid addiction
Trump administration allocates $50M for ibogaine research
10/6/2026
DemeRx appoints ibogaine expert Juan Sanchez-Ramos
Sanchez-Ramos joins as DemeRx advances its alcohol use disorder program.
10/6/2026
FDA input sought on ibogaine trial design
Guidance requested for early-phase ibogaine protocols amid regulatory challenges.
10/6/2026
FDA seeks public input on ibogaine clinical trials
Public comments sought on trial design, dosing, and safety for ibogaine studies.
10/6/2026
FDA outlines framework for ibogaine trials
New FDA notice suggests guidelines for ibogaine clinical research.
10/5/2026
FDA seeks public input on ibogaine research
Agency requests feedback on clinical trial design for ibogaine drug products.
9/15/2026
Psychedelic therapies cited by Trump: key insights
Trump's mention of psychedelic therapies sparks renewed interest in their potential applications.
8/26/2026
Americans face risks at overseas psychedelic clinics
Ibogaine treatments in Mexico raise safety concerns for U.S. patients.
8/26/2026
University of Miami gifts 1994 ibogaine IND to HHS
The move promotes open science and could influence future psychedelic research.
8/18/2026
University of Miami gifts ibogaine application to FDA
The move aims to expedite ibogaine research under a new executive order.
7/30/2026
Scottsdale Research Institute submits new ibogaine IND
The institute seeks approval to study ibogaine's potential in treating addiction.
7/29/2026
Scottsdale Research Institute submits IND for ibogaine
Ibogaine HCl aims to treat PTSD, TBI, and opioid use disorder.
7/24/2026
Joe Rogan's ibogaine advocacy sparks White House tension
Rogan's push for ibogaine approval led to conflict with a key Trump aide.